BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patriarca F, Carobolante F, Zamagni E, Montefusco V, Bruno B, Englaro E, Nanni C, Geatti O, Isola M, Sperotto A, Buttignol S, Stocchi R, Corradini P, Cavo M, Fanin R. The Role of Positron Emission Tomography with 18F-Fluorodeoxyglucose Integrated with Computed Tomography in the Evaluation of Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2015;21:1068-73. [DOI: 10.1016/j.bbmt.2015.03.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Shah SN, Oldan JD. PET/MR Imaging of Multiple Myeloma. Magn Reson Imaging Clin N Am 2017;25:351-65. [PMID: 28390534 DOI: 10.1016/j.mric.2017.01.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
2 Gerke O, Ehlers K, Motschall E, Høilund-Carlsen PF, Vach W. PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues. Mol Imaging Biol 2020;22:33-46. [PMID: 31016638 DOI: 10.1007/s11307-019-01351-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
3 Mosci C, Pericole FV, Oliveira GB, Delamain MT, Takahashi MES, Carvalheira JBC, Etchebehere ECSC, Santos AO, Miranda ECM, Lima MCL, Amorim BJ, de Souza CA, Lorand-Metze I, Ramos CD. 99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma. Nucl Med Commun 2020;41:1081-8. [PMID: 32732603 DOI: 10.1097/MNM.0000000000001259] [Reference Citation Analysis]
4 Nanni C, Zamagni E. Therapy assessment in multiple myeloma with PET. Eur J Nucl Med Mol Imaging 2017;44:111-7. [DOI: 10.1007/s00259-017-3730-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
5 Sachpekidis C, Goldschmidt H, Dimitrakopoulou-Strauss A. Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma. Molecules 2019;25:E134. [PMID: 31905752 DOI: 10.3390/molecules25010134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kaddoura M, Dingli D, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Kapoor P, Hwa L, Fonder A, Hobbs M, Hayman S, Lust J, Leung N, Go RS, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle RA, Broski SM, Rajkumar V, Kumar S. Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma. Blood Adv 2021;5:2753-9. [PMID: 34242392 DOI: 10.1182/bloodadvances.2020004131] [Reference Citation Analysis]
7 Sachpekidis C, Goldschmidt H, Dimitrakopoulou-Strauss A. [Positron emission tomography/computed tomography (PET/CT) in multiple myeloma]. Radiologe 2021. [PMID: 34921323 DOI: 10.1007/s00117-021-00948-7] [Reference Citation Analysis]
8 Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos M, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. The Lancet Oncology 2017;18:e206-17. [DOI: 10.1016/s1470-2045(17)30189-4] [Reference Citation Analysis]
9 Hughes NM, Jacene HA. PET Imaging for Hematologic Malignancies. Radiol Clin North Am 2021;59:705-23. [PMID: 34392914 DOI: 10.1016/j.rcl.2021.05.003] [Reference Citation Analysis]
10 Vicentini JRT, Bredella MA. Role of FDG PET in the staging of multiple myeloma. Skeletal Radiol 2021. [PMID: 33813607 DOI: 10.1007/s00256-021-03771-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zadeh MZ, Raynor WY, Seraj SM, Ayubcha C, Kothekar E, Werner T, Alavi A. Evolving Roles of Fluorodeoxyglucose and Sodium Fluoride in Assessment of Multiple Myeloma Patients. PET Clinics 2019;14:341-52. [DOI: 10.1016/j.cpet.2019.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
12 Ripani D, Caldarella C, Za T, Pizzuto DA, Rossi E, De Stefano V, Giordano A. Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation. Eur J Nucl Med Mol Imaging 2019;46:116-28. [PMID: 30054697 DOI: 10.1007/s00259-018-4108-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
13 Stolzenburg A, Lückerath K, Samnick S, Speer M, Kneer K, Schmid J, Grigoleit GU, Hofmann S, Beer AJ, Bunjes D, Knop S, Buck AK, Einsele H, Lapa C. Prognostic value of [18F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantation. Eur J Nucl Med Mol Imaging 2018;45:1694-704. [DOI: 10.1007/s00259-018-3997-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zamagni E, Cavo M, Fakhri B, Vij R, Roodman D. Bones in Multiple Myeloma: Imaging and Therapy. Am Soc Clin Oncol Educ Book 2018;38:638-46. [PMID: 30231385 DOI: 10.1200/EDBK_205583] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
15 Kumar S, Glazebrook KN, Broski SM. Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma. PET Clin 2019;14:391-403. [PMID: 31084778 DOI: 10.1016/j.cpet.2019.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Tu H, He Y, Huang T, Choe S, Lan X, Duan X, Sattar H, Li C, Zhou F. Predictive value of 18 F-FDG PET/CT scanning in combination with clinical parameters in patients with newly diagnosed multiple myeloma. Eur J Haematol 2018;100:189-97. [PMID: 29226428 DOI: 10.1111/ejh.13006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
17 Cui J, Zou Z, Duan J, Tang W, Li Y, Zhang L, Pan L, Niu T. Predictive Values of PET/CT in Combination With Regulatory B Cells for Therapeutic Response and Survival in Contemporary Patients With Newly Diagnosed Multiple Myeloma. Front Immunol 2021;12:671904. [PMID: 34489930 DOI: 10.3389/fimmu.2021.671904] [Reference Citation Analysis]
18 Ferrarazzo G, Chiola S, Capitanio S, Donegani MI, Miceli A, Raffa S, Tagliafico AS, Morbelli S, Bauckneht M. Positron Emission Tomography (PET) Imaging of Multiple Myeloma in a Post-Treatment Setting. Diagnostics (Basel) 2021;11:230. [PMID: 33546455 DOI: 10.3390/diagnostics11020230] [Reference Citation Analysis]
19 Li Q, Hu L, Charwudzi A, Zhu W, Meng Y, Zhai Z. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at diagnosis in untreated multiple myeloma patients: a systematic review and meta-analysis. Clin Exp Med 2022. [PMID: 35000022 DOI: 10.1007/s10238-021-00775-z] [Reference Citation Analysis]
20 Jung SH, Kwon SY, Min JJ, Bom HS, Ahn SY, Jung SY, Lee SS, Park MR, Yang DH, Ahn JS, Kim HJ, Lee JJ. 18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. Eur J Nucl Med Mol Imaging 2019;46:107-15. [PMID: 30187105 DOI: 10.1007/s00259-018-4114-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
21 Terpos E, Dimopoulos MA, Moulopoulos LA. The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. Am Soc Clin Oncol Educ Book 2016;35:e407-17. [PMID: 27249748 DOI: 10.1200/EDBK_159074] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
22 Nanni C, Zamagni E. Fluorodeoxyglucose-PET/Computed Tomography as a Predictor of Prognosis in Multiple Myeloma. PET Clin 2019;14:383-9. [PMID: 31084777 DOI: 10.1016/j.cpet.2019.03.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
23 Jamet B, Bailly C, Carlier T, Touzeau C, Nanni C, Zamagni E, Barré L, Michaud AV, Chérel M, Moreau P, Bodet-Milin C, Kraeber-Bodéré F. Interest of Pet Imaging in Multiple Myeloma. Front Med (Lausanne) 2019;6:69. [PMID: 31024917 DOI: 10.3389/fmed.2019.00069] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
24 Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol 2017;18:e206-17. [PMID: 28368259 DOI: 10.1016/S1470-2045(17)30189-4] [Cited by in Crossref: 202] [Cited by in F6Publishing: 110] [Article Influence: 40.4] [Reference Citation Analysis]
25 Kendler DL, Body JJ, Brandi ML, Broady R, Cannata-Andia J, Cannata-Ortiz MJ, El Maghraoui A, Guglielmi G, Hadji P, Pierroz DD, de Villiers TJ, Rizzoli R, Ebeling PR; International Osteoporosis Foundation Committee of Scientific Advisors Working Group on Cancer and Bone Disease. Bone management in hematologic stem cell transplant recipients. Osteoporos Int 2018;29:2597-610. [PMID: 30178158 DOI: 10.1007/s00198-018-4669-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
26 Zamagni E, Tacchetti P, Cavo M. Imaging in multiple myeloma: How? When? Blood 2019;133:644-51. [PMID: 30587527 DOI: 10.1182/blood-2018-08-825356] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
27 Zhong X, Diao W, Zhao C, Jia Z. Fluorodeoxyglucose-avid focal lesions and extramedullary disease on 18F-FDG PET/computed tomography predict the outcomes of newly diagnosed symptomatic multiple myeloma patients. Nucl Med Commun 2020;41:950-8. [PMID: 32796484 DOI: 10.1097/MNM.0000000000001242] [Reference Citation Analysis]
28 Rubini G, Niccoli-asabella A, Ferrari C, Racanelli V, Maggialetti N, Dammacco F. Myeloma bone and extra-medullary disease: Role of PET/CT and other whole-body imaging techniques. Critical Reviews in Oncology/Hematology 2016;101:169-83. [DOI: 10.1016/j.critrevonc.2016.03.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
29 Zamagni E, Tacchetti P, Terragna C, Cavo M. Multiple myeloma: disease response assessment. Expert Review of Hematology 2016;9:831-7. [DOI: 10.1080/17474086.2016.1212654] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
30 Barwick T, Bretsztajn L, Wallitt K, Amiras D, Rockall A, Messiou C. Imaging in myeloma with focus on advanced imaging techniques. Br J Radiol 2019;92:20180768. [PMID: 30604631 DOI: 10.1259/bjr.20180768] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
31 Mosebach J, Shah S, Delorme S, Hielscher T, Goldschmidt H, Schlemmer HP, Schönland S, Hegenbart U, Hillengass J. Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation. Haematologica 2018;103:336-43. [PMID: 29217779 DOI: 10.3324/haematol.2017.176073] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
32 Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. Haematologica 2018;103:1772-84. [PMID: 30171031 DOI: 10.3324/haematol.2018.189159] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 9.8] [Reference Citation Analysis]